Skip to main content
. Author manuscript; available in PMC: 2013 Jul 20.
Published in final edited form as: Vaccine. 2012 Jun 9;30(34):5099–5109. doi: 10.1016/j.vaccine.2012.05.067

Figure 1.

Figure 1

A. Pyrogenicity ± standard deviation over a 4 hr period and enhancement of lethal LPS shock (Alive/Total) by 500 μg/kg TSST-1 (■), G31S/S32P (◆), H135A (▲), and Q136A (●). TSST-1, G31S/S32P, H135A, and Q136A were administered intravenously at 0 hr; LPS (100μg/kg) was administered intravenously at 4 hr, just after taking the 4 hr temperatures. Alive/Total refers to the number of animals that survived as measured 48 hr post LPS injection.

B. Pyrogenicity on day 2 ± standard deviation and lethality over a 7 day period due to TSST-1, G31S/S32P, H135A, and Q136A administered subcutaneously as 1000 μg/miniosmotic pump.